Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 374

Sort by

Sort Order Select

Journal Articles

Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs

Christian A. Di Buduo, Silvia Giannini, Vittorio Abbonante, Vittorio Rosti, Karin M. Hoffmeister, Alessandra Balduini

Blood (2021) 137 (15): 2085–2089.

https://doi.org/10.1182/blood.2020007265

Published: 2021

Includes: Supplemental data

Journal Articles

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Blood (2019) 134 (26): 2388–2398.

https://doi.org/10.1182/blood.2019001385

Published: 2019

Includes: Supplemental data

Journal Articles

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Manjola Balliu, PhD, Laura Calabresi, PhD, Niccolò Bartalucci, PhDBSc, Laura Maggi, PhD, Francesco Annunziato, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 471.

https://doi.org/10.1182/blood-2019-123685

Published: 2019

Journal Articles

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Prithviraj Bose, MD, Moshe Talpaz, MD, Claire N Harrison, Professor, Vikas Gupta, MD FRCP, FRCPath, Brian Leber, MD, Shireen Sirhan, MD, Sujan Kabir, MD, Adrian Senderowicz, MD, James Shao, MS, Jennifer Mertz, PhD, Patrick Trojer, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 670.

https://doi.org/10.1182/blood-2019-127119

Published: 2019

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPharm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison, Professor

Blood (2019) 134 (Supplement_1): 704.

https://doi.org/10.1182/blood-2019-129020

Published: 2019

Journal Articles

Stratification of Responders and Non-Responders in the Reach-1 Trial Based on Serum Proteomic Analysis

Sherry Owens, PhD, Michael A. Pratta, MSc, Hao Liu, PhD, Michael C. Arbushites, Chuan Tian, PhD, Michael D. Howell, PhD

Blood (2019) 134 (Supplement_1): 4531.

https://doi.org/10.1182/blood-2019-127147

Published: 2019

Journal Articles

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Kidist Ashami, BA, Sena Kim, PhD, Ravi Vij, MBBS, Julie K. Ritchey, Srikanth Santhanam, PhD, Sora Lim, MS, Sarah Peterson, Matthew Ciorba, MD, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2019) 134 (Supplement_1): 4420.

https://doi.org/10.1182/blood-2019-126167

Published: 2019

Journal Articles

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Jingbo Yu, PhD, Jonathan K. Kish, PhD MPH, Dilan Paranagama, PhD, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 5385.

https://doi.org/10.1182/blood-2019-123833

Published: 2019

Journal Articles

Increased Frequency of Thromboses Among Patients with Philadelphia (Ph) Negative Myeloproliferative Neoplasms in New Mexico: The Role of Prothrombotic Risk Factors

Qiuying Selina Liu, MD, Shashank Y. Cingam, MBBS, Khine Z Win, MD, Tawny Boyce, MS, MPH, Cecilia Y. Arana Yi, MD

Blood (2019) 134 (Supplement_1): 5379.

https://doi.org/10.1182/blood-2019-132142

Published: 2019

Journal Articles

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Ivy Altomare, MD, Anna Nguyen, PharmD, MPH, Shreekant Parasuraman, BPharm, PhD, Dilan Paranagama, PhD, Jonathan K. Kish, PhD MPH, Kevin Lord, PhD MHS, Philomena Colucci, DO, MS

Blood (2019) 134 (Supplement_1): 4192.

https://doi.org/10.1182/blood-2019-127442

Published: 2019

Journal Articles

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

Claire N Harrison, Professor, Andrea Patriarca, MD, John Mascarenhas, MD, Marina Kremyanskaya, Ronald Hoffman, MD, Gary J. Schiller, MD, Brian Leber, MD, Timothy Devos, MD PhD, Sujan Kabir, MD, Adrian Senderowicz, MD, Jennifer Mertz, PhD, Patrick Trojer, PhD, James Shao, MS, Vikas Gupta, MD FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 4164.

https://doi.org/10.1182/blood-2019-128211

Published: 2019

Journal Articles

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Jason Gotlib, MD MS, Nashat Gabrail, MD, Casey L. O'Connell, MD, Regina Garcia-Delgado, MD, Timothy Sbardellati, Wayne M. Rothbaum, Jesse McGreivy, Claire N Harrison, Professor, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 4168.

https://doi.org/10.1182/blood-2019-123546

Published: 2019

Journal Articles

Brefeldin Α Reduces STAT3 Dependent Survival of Acute Leukemia and Neuroblastoma Cells

Mitsuteru Hiwatari, MD PhD, Kentaro Watanabe, MD, Yasuo Kubota, MD, Masahiro Sekiguchi, MD, Junko Takita, MD PhD

Blood (2019) 134 (Supplement_1): 5762.

https://doi.org/10.1182/blood-2019-130056

Published: 2019

Journal Articles

Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Annie Im, MD, Rodica Morariu-Zamfir, MD, Maureen Bleam, BS, Ying Yan, PhD, Steven Z. Pavletic, MD MS

Blood (2019) 134 (Supplement_1): 3277.

https://doi.org/10.1182/blood-2019-128586

Published: 2019

Journal Articles

Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare

Ruth-Anne Langan, BA, Alberto Japp, PhD, Michael Gonzalez, PhD, Rozena Rasheed, BS, Sheila K Pierson, MS, Charlly Kao, PhD, Hakon Hakonarson, MD PhD, Frits van Rhee, MD PhD, Michael Betts, PhD, Taku Kambayashi, MD PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2019) 134 (Supplement_1): 1046.

https://doi.org/10.1182/blood-2019-128994

Published: 2019

Journal Articles

Congenital STAT3 mutation Mediates Primary Persistent Polymorphic Inflammatory Activation and T Cell Leukemogenesis

Hongxing Liu

Blood (2019) 134 (Supplement_1): 1054.

https://doi.org/10.1182/blood-2019-132138

Published: 2019

Journal Articles

Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells

Uri Rozovski, MD, David M. Harris, PhD, Ping Li, PhD, Zhiming Liu, BS, Taghi Manshouri, PhD, Ivo Veletic, MD, Preetesh Jain, MBBS,MDDM,PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, Srdan Verstovsek, MD PhD, William G. Wierda, MD PhD, Michael J Keating, MBBS, Zeev E. Estrov, MD

Blood (2019) 134 (Supplement_1): 3018.

https://doi.org/10.1182/blood-2019-124014

Published: 2019

Journal Articles

STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes

Taghi Manshouri, PhD, Ivo Veletic, MD, Ying Zhang, MD MS, Joseph E. Bove, IV, BS, Ping Li, PhD, David M. Harris, PhD, Zhiming Liu, BS, Evan N. Cohen, PhD, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD

Blood (2019) 134 (Supplement_1): 2961.

https://doi.org/10.1182/blood-2019-132054

Published: 2019

Journal Articles

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Stephan Wilmes, PhD, Maximillian Hafer, BSc, Tess A Stanly, Ignacio Moraga, PhD, Joni Vuorio, PhD, Chetan Poojari, PhD, Vivek Sharma, PhD, Sara Löchte, PhD, Katiuska Pulgar Prieto, BSc, Julie A Tucker, PhD, Stevan R Hubbard, PhD, K.Christopher Garcia, PhD, Ilpo Vattulainen, PhD, Ian Hitchcock, PhD, Jacob Piehler, PhD

Blood (2019) 134 (Supplement_1): 2962.

https://doi.org/10.1182/blood-2019-129234

Published: 2019

Journal Articles

Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL

Blood (2019) 134 (Supplement_1): 3024.

https://doi.org/10.1182/blood-2019-124183

Published: 2019

NARROW

Increased B4GALT1 expression is associated with platelet surface galactosylation and thrombopoietin plasma levels in MPNs

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

Stratification of Responders and Non-Responders in the Reach-1 Trial Based on Serum Proteomic Analysis

Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair

Persistence of Ruxolitinib Treatment in Patients with Myelofibrosis at Community Oncology Practices in the United States-Contemporary Data

Increased Frequency of Thromboses Among Patients with Philadelphia (Ph) Negative Myeloproliferative Neoplasms in New Mexico: The Role of Prothrombotic Risk Factors

Real-World Dosing Patterns of Ruxolitinib in Patients with Polycythemia Vera Who Are Resistant to or Intolerant of Hydroxyurea

Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients

A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia Vera

Brefeldin Α Reduces STAT3 Dependent Survival of Acute Leukemia and Neuroblastoma Cells

Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)

Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare

Congenital STAT3 mutation Mediates Primary Persistent Polymorphic Inflammatory Activation and T Cell Leukemogenesis

Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells

STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes

New Paradigms for the Mechanisms of Thrombopoietin Receptor Activation and Dysregulation By the JAK2 V617F Mutation

Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only